Three-in-One Portfolio Theory

Financial advisor voice: the triple agonist isn't a peptide, it's an index fund with delta-4 receptor exposure.

Filed under Retatrutide ·Tirzepatide ·Survodutide · #glp-1 ·#stack-life ·#cope

Active Compounds

Retatrutide · Triple GIP/GLP-1/Glucagon Receptor Agonist

An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.

Tirzepatide · Dual GIP/GLP-1 Receptor Agonist

A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

RX: Retatrutide · Tirzepatide · Survodutide
Dosage: 3 receptors, 1 syringe
Half-life: one fiscal quarter
Source: manual
Tags: glp-1 , stack-life , cope
Stamped: 2026-09-19 · Cycle 038
Lot #: LOT-20260919T21:13:50.727Z